Is REGN a good stock to buy? We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.’s share was trading at $616.18 as of June 9th. REGN’s trailing and forward P/E were 15.51 and 14.16 respectively according to Yahoo Finance.
Pressmaster/Shutterstock.com
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. REGN is increasingly mischaracterized by the market as a one-product story centered on Dupixent, but this framing understates the depth of its innovation engine and long-duration cash flow visibility. Dupixent already generates over $14 billion in annual sales across atopic dermatitis, asthma, COPD, and prurigo nodularis, and remains co-developed with Sanofi, providing royalty streams extending beyond 2031.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
However, the core investment case is anchored in Regeneron’s differentiated R&D platform, particularly the Regeneron Genetics Center, which has sequenced over 3 million exomes in collaboration with UK Biobank, enabling proprietary identification of genetically validated drug targets at unmatched scale. This approach materially improves clinical success rates and has produced programs such as PCSK9 inhibitor Praluent and is now feeding next-generation obesity combinations including amycretin and trevogrumab.
The VelociGene platform further compresses timelines by enabling rapid generation of fully human antibodies and accelerated clinical entry. Despite these advantages, the market prices REGN with focus on Dupixent biosimilar risk and GLP-1 competition in inflammatory indications. At the same time, the company trades at a discount to its five-year average NTM P/E despite strong free cash flow and ongoing aggressive share repurchases.
Near-term oncology catalysts, including linvoseltamab and fianlimab, represent underappreciated binary upside drivers. Overall, Regeneron Pharmaceuticals presents a mispriced platform story where investors anchor on patent cliff concerns while underestimating the expanding R&D engine and long-duration earnings power making it an attractive opportunity for patient long term investors.
Previously, we covered a bullish thesis on Eli Lilly and Company (LLY) by Kontra in May 2025, which highlighted obesity and diabetes leadership driven by GLP-1 growth and pipeline expansion. LLY’s stock price has appreciated by approximately 44.14% since our coverage. Variant_Invest shares a similar view but emphasizes Regeneron Pharmaceuticals’ platform-driven genetics R&D engine, highlighting undervalued innovation breadth beyond Dupixent dependence.
Regeneron Pharmaceuticals, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 72 hedge fund portfolios held REGN at the end of the first quarter which was 75 in the previous quarter. While we acknowledge the risk and potential of REGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than REGN and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
